Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 29, 2023
The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate CancerMarinus J Hagens, Wietske I Luining, Auke Jager, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary CancersMarinus J Hagens, Pim J van Leeuwen, Maurits Wondergem, et al.Clinical Genitourinary Cancer|March 14, 2023
Added Clinical Value of <sup>18</sup>F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical CystectomyNoor van Ginkel, Erik J van Gennep, Liselot Oosterbaan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 11, 2013
99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolizationMaurits Wondergem, Maarten L J Smits, Mattijs Elschot, et al.Clinical Nuclear Medicine|April 22, 2022
18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?Bernies van der Hiel, Stephanie A Blankenstein, Else A Aalbersberg, et al.BJU International|May 29, 2023
Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based studyAnke Richters, Noor van Ginkel, Richard P Meijer, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 25, 2024
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancerMaarten L Donswijk, Rosemarijn H Ettema, Dennie Meijer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2019
Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for <sup>18</sup>F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate CancerBernard H E Jansen, Robin W Jansen, Maurits Wondergem, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2025
[<sup>18</sup>F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trialSabine E Breukers, Robert D Crommelin, Laura A Smit, et al.Plos One|October 6, 2020
Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancerDennie Meijer, Bernard H E Jansen, Maurits Wondergem, et al.Pageof 6